Literature DB >> 27566487

The Role of the Microenvironment in Prostate Cancer-Associated Bone Disease.

Christina J Turner1, Claire M Edwards2,3.   

Abstract

The bone is a common site for metastasis in patients with advanced prostate carcinoma, and provides a 'fertile' milieu which stimulates tumour growth and associated bone disease. For years, the concept of treatment strategies has remained targeting the tumour itself; however, the occurrence of chemoresistance remains a challenge now more than ever. The attraction of targeting the bone microenvironment in order to disrupt tumour localisation and proliferation stems from the idea that stromal cells are superiorly stable at a genetic level, thus decreasing the risk of resistance manifestation. In this review, we will discuss recent findings with regards to the pathogenesis of prostate cancer-induced bone disease and recent therapeutic strategies in an aim to evaluate the ever increasing role of the microenvironment in disease progression.

Entities:  

Keywords:  Bone metastasis; Bone microenvironment; Prostate cancer; Therapeutic strategies

Mesh:

Substances:

Year:  2016        PMID: 27566487     DOI: 10.1007/s11914-016-0323-2

Source DB:  PubMed          Journal:  Curr Osteoporos Rep        ISSN: 1544-1873            Impact factor:   5.096


  57 in total

Review 1.  Metastasis to bone: causes, consequences and therapeutic opportunities.

Authors:  Gregory R Mundy
Journal:  Nat Rev Cancer       Date:  2002-08       Impact factor: 60.716

2.  Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study.

Authors:  Giuseppe Di Lorenzo; William D Figg; Sophie D Fossa; Vincenzo Mirone; Riccardo Autorino; Nicola Longo; Ciro Imbimbo; Sisto Perdonà; Antonio Giordano; Mario Giuliano; Roberto Labianca; Sabino De Placido
Journal:  Eur Urol       Date:  2008-02-05       Impact factor: 20.096

Review 3.  Microenvironmental regulation of tumor progression and metastasis.

Authors:  Daniela F Quail; Johanna A Joyce
Journal:  Nat Med       Date:  2013-11       Impact factor: 53.440

4.  Infiltrating bone marrow mesenchymal stem cells increase prostate cancer stem cell population and metastatic ability via secreting cytokines to suppress androgen receptor signaling.

Authors:  J Luo; S Ok Lee; L Liang; C-K Huang; L Li; S Wen; C Chang
Journal:  Oncogene       Date:  2013-06-24       Impact factor: 9.867

5.  Mitotic quiescence, but not unique "stemness," marks the phenotype of bone metastasis-initiating cells in prostate cancer.

Authors:  Ning Wang; Freyja Docherty; Hannah K Brown; Kim Reeves; Anne Fowles; Michelle Lawson; Penelope D Ottewell; Ingunn Holen; Peter I Croucher; Colby L Eaton
Journal:  FASEB J       Date:  2015-04-17       Impact factor: 5.191

Review 6.  RANKL/RANK/OPG: key therapeutic target in bone oncology.

Authors:  Kosei Ando; Kanji Mori; Francoise Rédini; Dominique Heymann
Journal:  Curr Drug Discov Technol       Date:  2008-09

Review 7.  Anti-angiogenesis or pro-angiogenesis for cancer treatment: focus on drug distribution.

Authors:  Dongsheng Huang; Huanrong Lan; Fanlong Liu; Shibing Wang; Xiaoyi Chen; Ketao Jin; Xiaozhou Mou
Journal:  Int J Clin Exp Med       Date:  2015-06-15

8.  Recruitment of mesenchymal stem cells into prostate tumours promotes metastasis.

Authors:  Younghun Jung; Jin Koo Kim; Yusuke Shiozawa; Jingcheng Wang; Anjali Mishra; Jeena Joseph; Janice E Berry; Samantha McGee; Eunsohl Lee; Hongli Sun; Jianhua Wang; Taocong Jin; Honglai Zhang; Jinlu Dai; Paul H Krebsbach; Evan T Keller; Kenneth J Pienta; Russell S Taichman
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

Review 9.  Pathobiology and management of prostate cancer-induced bone pain: recent insights and future treatments.

Authors:  Arjun Muralidharan; Maree T Smith
Journal:  Inflammopharmacology       Date:  2013-08-06       Impact factor: 4.473

10.  Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance.

Authors:  Kari R Fischer; Anna Durrans; Sharrell Lee; Jianting Sheng; Fuhai Li; Stephen T C Wong; Hyejin Choi; Tina El Rayes; Seongho Ryu; Juliane Troeger; Robert F Schwabe; Linda T Vahdat; Nasser K Altorki; Vivek Mittal; Dingcheng Gao
Journal:  Nature       Date:  2015-11-11       Impact factor: 49.962

View more
  6 in total

Review 1.  Interaction between prostate cancer stem cells and bone microenvironment regulates prostate cancer bone metastasis and treatment resistance.

Authors:  Lu Yao; Xiangyu Zhang
Journal:  J Cancer       Date:  2022-06-13       Impact factor: 4.478

2.  Prostate cancer promotes a vicious cycle of bone metastasis progression through inducing osteocytes to secrete GDF15 that stimulates prostate cancer growth and invasion.

Authors:  Wenchu Wang; Xin Yang; Jinlu Dai; Yi Lu; Jian Zhang; Evan T Keller
Journal:  Oncogene       Date:  2019-02-12       Impact factor: 8.756

3.  Humanized bone facilitates prostate cancer metastasis and recapitulates therapeutic effects of zoledronic acid in vivo.

Authors:  Marietta Landgraf; Christoph A Lahr; Alvaro Sanchez-Herrero; Christoph Meinert; Ali Shokoohmand; Pamela M Pollock; Dietmar W Hutmacher; Abbas Shafiee; Jacqui A McGovern
Journal:  Bone Res       Date:  2019-10-21       Impact factor: 13.567

4.  Osteoblasts Promote Prostate Cancer Cell Proliferation Through Androgen Receptor Independent Mechanisms.

Authors:  Giulia Ribelli; Sonia Simonetti; Michele Iuliani; Elisabetta Rossi; Bruno Vincenzi; Giuseppe Tonini; Francesco Pantano; Daniele Santini
Journal:  Front Oncol       Date:  2021-12-13       Impact factor: 6.244

Review 5.  Interactions between cancer cells and bone microenvironment promote bone metastasis in prostate cancer.

Authors:  Xiangyu Zhang
Journal:  Cancer Commun (Lond)       Date:  2019-11-21

Review 6.  Metabolism in the Tumour-Bone Microenvironment.

Authors:  Jessica Whitburn; Claire M Edwards
Journal:  Curr Osteoporos Rep       Date:  2021-07-28       Impact factor: 5.096

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.